Centers for Disease Control Prevention. Interim guidance for clinicians considering the use of preexposure prophylaxis for the prevention of HIV infection in heterosexually active adults. MMWR Morb Mortal Wkly Rep. 2012;61(31):586–9.
US Food and Drug Administration. FDA approves second drug to prevent HIV infection as part of ongoing efforts to end the HIV epidemic. FDA News Release. Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-second-drug-prevent-hiv-infection-part-ongoing-efforts-end-hiv-epidemic . Accessed date: January 14, 20232019.
US Food and Drug Administration. FDA approves first injectable treatment for HIV pre-exposure prevention. 2019. FDA News Release. Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-first-injectable-treatment-hiv-pre-exposure-prevention . Accessed Date: January 14, 2023.2019.
Centers for Disease Control Prevention. Pre-exposure prophylaxis for the prevention of HIV infection in the United States - 2021 update. Available at: https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2021.pdf . Accessed Date: January 14, 20232021.
Molina J, Ghosn J, Béniguel L, Rojas-Castro D, Algarte-Genin M, Pialoux G. Incidence of HIV-infection in the ANRS Prevenir study in Paris region with daily or on-demand PrEP with TDF/FTC. Age (years). 2018;36:30–44.
Molina J-M, Charreau I, Spire B, Cotte L, Chas J, Capitant C, et al. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study. The lancet HIV. 2017;4(9):e402–10.
Zhang J, Xu JJ, Wang HY, Huang XJ, Chen YK, Wang H, et al. Preference for daily versus on-demand pre-exposure prophylaxis for HIV and correlates among men who have sex with men: the China Real-world Oral PrEP Demonstration study. J Int AIDS Soc. 2021;24(2):e25667.
Article CAS PubMed PubMed Central Google Scholar
James S, Herman J, Rankin S, Keisling M, Mottet L, Anafi Ma. The report of the 2015 US transgender survey. 2016.
Scheim AI, Baker KE, Restar AJ, Sell RL. Health and health care among transgender adults in the United States. Annual Review of Public Health. 2022;43:503–23. This article summarizes the multiple healthcare disparities and inequities documented among trans populations in the US.
Goldenberg T. Health care use among transgender and other gender diverse people in the United States: influences of stigma and resilience 2019.
Hughto JMW, Reisner SL, Pachankis JE. Transgender stigma and health: a critical review of stigma determinants, mechanisms, and interventions. Soc Sci Med. 2015;147:222–31.
Becasen JS, Denard CL, Mullins MM, Higa DH, Sipe TA. Estimating the prevalence of HIV and sexual behaviors among the US transgender population: a systematic review and meta-analysis, 2006–2017. American journal of public health. 2019;109(1):e1-e8. This article is a meta-analysis of lab-confirmed HIV results among trans populations in the city, stratified by race/ethnicity.
Tordoff DM, Minalga B, Gross BB, Martin A, Caracciolo B, Barbee LA, et al. Erasure and health equity implications of using binary male/female categories in sexual health research and human immunodeficiency virus/sexually transmitted infection surveillance: recommendations for transgender-inclusive data collection and reporting. Sex Transm Dis. 2022;49(2):e45–9.
Article PubMed PubMed Central Google Scholar
McNulty A, Bourne C. Transgender HIV and sexually transmissible infections. Sexual Health. 2017;14(5):451–5.
Minalga B, Chung C, Davids J, Martin A, Perry NL, Shook A. Research on transgender people must benefit transgender people. The Lancet. 2022;399(10325):628.
Operario D, Restar A. Gender-affirmative systems needed for PrEP implementation. The Lancet HIV. 2020;7(12):e799–800.
Scheim AI, Appenroth MN, Beckham SW, Goldstein Z, Grinspan MC, Keatley JG, et al. Transgender HIV research: nothing about us without us. The Lancet HIV. 2019;6(9):e566–7.
Article PubMed PubMed Central Google Scholar
Adimora AA, Auerbach JD. Structural interventions for HIV prevention in the United States. J Acquir Immune Defic Syndr. 2010;55(0 2):S132.
Article PubMed PubMed Central Google Scholar
Restar A, Jin H, Operario D. Gender-inclusive and gender-specific approaches in trans health research. Transgender Health. 2021;6(5):235–9.
Article PubMed PubMed Central Google Scholar
Grant RM, Sevelius JM, Guanira JV, Aguilar JV, Chariyalertsak S, Deutsch MB. Transgender women in clinical trials of pre-exposure prophylaxis. Journal of acquired immune deficiency syndromes (1999). 2016;72(Suppl 3):S226. This is a sub-analysis of trans women’s involvement in one of the first PrEP clinical trials.
Dang M, Scheim AI, Teti M, Quinn KG, Zarwell M, Petroll AE, et al. Barriers and facilitators to HIV pre-exposure prophylaxis uptake, adherence, and persistence among transgender populations in the United States: a systematic review. AIDS Patient Care STDS. 2022;36(6):236–48.
Cloete A, Skinner D, van der Merwe L, Lynch I. Community-derived interventions can improve responsiveness to the HIV prevention needs of transgender women in South Africa. (Paper presented at the Satellite HIVR4P: Getting to the Heart of Stigma: Removing Stigma as Barrier and Enhancing HIV Prevention Efforts). 2021.
Van Der Merwe L, Mavhandu-Mudzusi A. S06. 1 The healthcare experiences of transgender women living with HIV in the Buffalo City Metro Municipality. BMJ Publishing Group Ltd; 2021.
Lett E, Abrams MP, Gold A, Fullerton F-A, Everhart A. Ethnoracial inequities in access to gender-affirming mental health care and psychological distress among transgender adults. Soc Psychiatry Psychiatr Epidemiol. 2022;57(5):963–71. This article applies an intersectionality framework to both premise and methodology to delineate the racial/ethnic differences of gender-affirming care and mental health outcomes among trans people.
Lett E, Asabor EN, Tran N, Dowshen N, Aysola J, Gordon AR, et al. Sexual behaviors associated with HIV transmission among transgender and gender diverse young adults: the intersectional role of racism and transphobia. AIDS Behav. 2022;1–13.
Restar A, Dusic E, Garrison-Desany H, Lett E, Everhart A, Baker KE, et al. Gender affirming hormone therapy dosing behaviors among transgender and nonbinary adults. Humanit Soc Sci Commun. 2022;9(1):1–11. This article documents the different dosing behaviors of gender affirming hormones among trans people, showing that not all trans people take or view hormones as part of their gender affirmation.
Bowleg L. “The master’s tools will never dismantle the master’s house”: ten critical lessons for Black and other health equity researchers of color. Health Educ Behav. 2021;48(3):237–49. This article discusses the key contexts on how to address pervasive oppressive systems of power perpetuate harms like cissexim and cisnormativity in the context of health equity research.
Wongkanya R, Pankam T, Wolf S, Pattanachaiwit S, Jantarapakde J, Pengnongyang S, et al. HIV rapid diagnostic testing by lay providers in a key population-led health service programme in Thailand. J Virus Erad. 2018;4(1):12–5.
Article PubMed PubMed Central Google Scholar
Phanuphak N, Sungsing T, Jantarapakde J, Pengnonyang S, Trachunthong D, Mingkwanrungruang P, et al. Princess PrEP program: the first key population-led model to deliver pre-exposure prophylaxis to key populations by key populations in Thailand. Sexual health. 2018;15(6):542–55.
van Griensven F, Janamnuaysook R, Nampaisan O, Peelay J, Samitpol K, Mills S, et al. Uptake of primary care services and HIV and syphilis infection among transgender women attending the Tangerine Community Health Clinic, Bangkok, Thailand, 2016–2019. J Int AIDS Soc. 2021;24(6):e25683.
Article PubMed PubMed Central Google Scholar
Gamarel KE, Rebchook G, McCree BM, Jadwin-Cakmak L, Connolly M, Reyes LA, et al. The ethical imperative to reduce HIV stigma through community-engaged, status-neutral interventions designed with and for transgender women of colour in the United States. J Int AIDS Soc. 2022;25:e25907.
Article PubMed PubMed Central Google Scholar
Vannakit R, Janyam S, Linjongrat D, Chanlearn P, Sittikarn S, Pengnonyang S, et al. Give the community the tools and they will help finish the job: key population-led health services for ending AIDS in Thailand. J Int AIDS Soc. 2020;23(6).
Yang F, Janamnuaysook R, Boyd MA, Phanuphak N, Tucker JD. Key populations and power: people-centred social innovation in Asian HIV services. The Lancet HIV. 2020;7(1):e69–74.
Janamnuaysook R, Green KE, Seekaew P, Vu BN, Van Ngo H, Doan HA, et al. Demedicalisation of HIV interventions to end HIV in the Asia-Pacific. Sexual Health. 2021;18(1):13–20.
Cargill VA. Valuing the vulnerable–the important role of transgender communities in biomedical research. Ethn Dis. 2020;30(2):247.
Article PubMed PubMed Central Google Scholar
Nunn AS, Brinkley-Rubinstein L, Oldenburg CE, Mayer KH, Mimiaga M, Patel R, et al. Defining the HIV pre-exposure prophylaxis care continuum. AIDS (London, England). 2017;31(5):731.
Sevelius JM, Deutsch MB, Grant R. The future of PrEP among transgender women: the critical role of gender affirmation in research and clinical practices. J Int AIDS Soc. 2016;19:21105.
Article PubMed PubMed Central Google Scholar
Sevelius JM, Dilworth SE, Reback CJ, Chakravarty D, Castro D, Johnson MO, et al. Randomized controlled trial of healthy divas: a gender-affirming, peer-delivered intervention to improve hIV care engagement among transgender women living with HIV. J Acquir Immune Defic Syndr (1999). 2022.
Sevelius J, Chakravarty D, Neilands TB, Keatley J, Shade SB, Johnson MO, et al. Evidence for the model of gender affirmation: the role of gender affirmation and healthcare empowerment in viral suppression among transgender women of color living with HIV. AIDS Behav. 2021;25(1):64–71.
Article PubMed PubMed Central Google Scholar
Bothma R, O’Connor C, Nkusi J, Shiba V, Segale J, Matsebula L, et al. Differentiated HIV services for transgender people in four South African districts: population characteristics and HIV care cascade. J Int AIDS Soc. 2022;25:e25987.
Article PubMed PubMed Central Google Scholar
Sevelius JM, Glidden DV, Deutsch M, Welborn L, Contreras A, Salinas A, et al. Uptake, retention, and adherence to pre-exposure prophylaxis (PrEP) in TRIUMPH: a peer-led PrEP demonstration project for transgender communities in Oakland and sacramento, California. J Acquir Immune Defic Syndr. 2021;88(1):S27.
Article PubMed PubMed Central Google Scholar
Harsono D, Galletly CL, O’Keefe E, Lazzarini Z. Criminalization of HIV exposure: a review of empirical studies in the United States. AIDS Behav. 2017;21(1):27–50.
Article PubMed PubMed Central Google Scholar
Gamarel KE, Jadwin-Cakmak L, King WM, Hughes L, Abad J, Trammell R, et al. Improving access to legal gender affirmation for transgender women involved in the criminal–legal system. J Correct Health Care. 2022.
Anderson PL, Reirden D, Castillo-Mancilla J. Pharmacologic considerations for preexposure prophylaxis in transgender women. J Acquir Immune Defic Syndr. 2016;72(Suppl 3):S230.
Article CAS PubMed PubMed Central Google Scholar
Yager JL, Anderson PL. Pharmacology and drug interactions with HIV PrEP in transgender persons receiving gender affirming hormone therapy. Expert Opin Drug Metab Toxicol. 2020;16(6):463–74.
Article CAS PubMed Google Scholar
Mehrotra ML, Westreich D, McMahan VM, Glymour MM, Geng E, Grant RM, et al. Baseline characteristics explain differences in effectiveness of randomization to daily oral TDF/FTC PrEP between transgender women and cisgender men who have sex with men in the iPrEx trial. J Acquir Immune Defic Syndr. 2019;81(3):e94.
Article PubMed PubMed Central Google Scholar
Grant RM, Pellegrini M, Defechereux PA, Anderson PL, Yu M, Glidden DV, et al. Sex hormone therapy and tenofovir diphosphate concentration in dried blood spots: primary results of the interactions between antiretrovirals and transgender hormones study. Clin Infect Dis. 2021;73(7):e2117–23.
Article CAS PubMed Google Scholar
Hiransuthikul A, Himmad L, Kerr SJ, Janamnuaysook R, Dalodom T, Phanjaroen K, et al. Drug-drug interactions among Thai transgender women living with human immunodeficiency undergoing feminizing hormone therapy and antiretroviral therapy: the iFACT Study. Clin Infect Dis. 2021;72(3):396–402.
Article CAS PubMed Google Scholar
Cespedes MS, Das M, Yager J, Prins M, Krznaric I, de Jong J, et al. Gender affirming hormones do not affect the exposure and efficacy of F/TDF or F/TAF for HIV preexposure prophylaxis: a subgroup analysis from the DISCOVER trial. Transgender Health. 2022.
Restar AJ, Santamaria EK, Adia A, Nazareno J, Chan R, Lurie M, et al. Gender affirmative HIV care framework: decisions on feminizing hormone therapy (FHT) and antiretroviral therapy (ART) among transgender women. PLoS One. 2019;14(10):e0224133.
留言 (0)